Navigation Links
HPS Files Comprehensive Patent Outside the Unites States for Mood-Enhancing Compound Naturally Found in Sea Coral
Date:1/15/2009

SAN JOSE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced that it has filed a Comprehensive Patent Application with the International Bureau of the World Patent Office for the use of its innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

"We recently announced that we had filed an application with the U.S. Patent and Trademark Office for this compound, labeled as ER 303, and we have now followed-up with a patent application with the International Bureau that will cover major countries outside the United States," a spokesperson indicated. "This unique technology has worldwide applications, and, as such, we are also seeking to protect its value in Europe and other primary consumer markets outside the United States. Seeking this protection is critical in that we are seeking licensing opportunities with companies having a worldwide marketing and product presence." The Company reiterated that prior to its reproduction of this compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.

The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates. An HPS spokesperson indicated that the Company believes that this additional filing on its new compound should be of interest to the major consumer products companies around the world.

This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10- KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rodobo International, Inc. Files Fiscal Year 2008 SEC Form 10-K
2. Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition
3. Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14-Month-Old Girl Killed in October 15th 2008 Medical Evacuation Helicopter Crash Near Aurora, Illinois
4. Scantek Medical Files for Chapter 11 Voluntary Bankruptcy and Receives Orders for the Sale of BreastCare(TM)
5. Californian Files Contact Lens Solution False Advertising Class Action Against Advanced Medical Optics, Announces the Schmidt Firm, LLP
6. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
7. AMERIGROUP Files Shelf Registration Statement
8. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
9. Bally Total Fitness Files for Chapter 11 Bankruptcy Protection
10. Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution
11. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... 2016 , ... The Society for Women’s Health Research (SWHR) announced that its ... role. , “No one in Washington led the way to advance women’s health research ... MD, PhD. “We offer our deep gratitude to Phyllis for her passion and performance ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... on its Chesterfield, Missouri, campus, Standard Process Inc. awarded $6,000 in ... Siewert and Chloe Tillman. Each student is in her fifth trimester of classes ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a leading treatment ... to announce the launch of its new extended care program, Fifth Circle. Available for ... Four Circles or another primary treatment program, Fifth Circle is designed to foster the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... 19, 2016 BioLineRx Ltd. (NASDAQ/TASE: ... the treatment of multiple cancer and hematological indications, will ... An abstract titled " Clinical response in relapsed/refractory AML ... by BL-8040, a potent CXCR4 antagonist; results of a ... presentation at the European Hematology Association 21st Congress, to ...
(Date:5/19/2016)... and CAMBRIDGE, Massachusetts , May 19, ... in the development of pharmaceuticals and diagnostics based on the ... a new office in Cambridge, MA ... US. The office is located at Kendall Square, ... industry, well-known as the global hub for transforming scientific insights ...
(Date:5/18/2016)... May 19, 2016 ... Research Report initially provides a basic overview ... and manufacturing technology, post which the report ... in the market. Complete report ... pages providing 8 company profiles and 98 ...
Breaking Medicine Technology: